Device type · CIG
Diazo Colorimetry, Bilirubin
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
CIG
Clinical Chemistry
Device class
Class II
FDA decisions since 2015
7
510(k), De Novo and PMA
Adverse event reports
58
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Diazo Colorimetry, Bilirubin
- Product code
- CIG
- Device class
- Class II
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1110
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for CIG
Latest FDA decisions
Siemens Healthcare Diagnostics, Inc.
K251998 · Decided Feb 27, 2026 · 245 days after receipt
Device type: Diazo Colorimetry, Bilirubin (CIG) · Laboratory Medicine & Pathology
Siemens Healthcare Diagnostics, Inc.
K223078 · Decided Jun 12, 2023 · 255 days after receipt
Device type: Diazo Colorimetry, Bilirubin (CIG) · Laboratory Medicine & Pathology
Siemens Healthcare Diagnostics, Inc.
K222104 · Decided Mar 20, 2023 · 245 days after receipt
Device type: Diazo Colorimetry, Bilirubin (CIG) · Laboratory Medicine & Pathology
- Total Bilirubin2510(k)
Abbott Ireland Diagnostics Division
K223324 · Decided Dec 29, 2022 · 59 days after receipt
Device type: Diazo Colorimetry, Bilirubin (CIG) · Laboratory Medicine & Pathology
Ortho-Clinical Diagnostics, Inc.
K190807 · Decided Apr 26, 2019 · 28 days after receipt
Device type: Diazo Colorimetry, Bilirubin (CIG) · Laboratory Medicine & Pathology
K171401 · Decided Jul 11, 2017 · 60 days after receipt
Device type: Diazo Colorimetry, Bilirubin (CIG) · Laboratory Medicine & Pathology
- Total Bilirubin510(k)
K150510 · Decided Apr 2, 2015 · 34 days after receipt
Device type: Diazo Colorimetry, Bilirubin (CIG) · Laboratory Medicine & Pathology
Reports received
58
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
58
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 3 | 0 | 0 | 0 |
| Jan 24 | 5 | 0 | 0 | 0 |
| Feb 24 | 2 | 0 | 0 | 0 |
| Mar 24 | 7 | 0 | 0 | 0 |
| Apr 24 | 2 | 0 | 0 | 0 |
| May 24 | 5 | 0 | 0 | 0 |
| Jun 24 | 4 | 0 | 0 | 0 |
| Jul 24 | 5 | 0 | 0 | 0 |
| Aug 24 | 1 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 4 | 0 | 0 | 0 |
| Nov 24 | 2 | 0 | 0 | 0 |
| Dec 24 | 2 | 0 | 0 | 0 |
| Jan 25 | 11 | 0 | 0 | 0 |
| Feb 25 | 4 | 0 | 0 | 0 |
| Mar 25 | 7 | 0 | 0 | 0 |
| Apr 25 | 4 | 0 | 0 | 0 |
| May 25 | 2 | 0 | 0 | 0 |
| Jun 25 | 1 | 0 | 0 | 0 |
| Jul 25 | 3 | 0 | 0 | 0 |
| Aug 25 | 9 | 0 | 0 | 0 |
| Sep 25 | 2 | 0 | 0 | 0 |
| Oct 25 | 4 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 5 | 0 | 0 | 0 |
| Jan 26 | 5 | 0 | 0 | 0 |
| Feb 26 | 5 | 0 | 0 | 0 |
| Mar 26 | 3 | 0 | 0 | 0 |
| Apr 26 | 5 | 0 | 0 | 0 |
| May 26 | 3 | 0 | 0 | 0 |
| Jun 26 | 8 | 0 | 0 | 0 |
| Jul 26 | 7 | 0 | 0 | 0 |
| Aug 26 | 4 | 0 | 0 | 0 |
| Sep 26 | 6 | 0 | 0 | 0 |
| Oct 26 | 7 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
- Abbott13
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results23
- Non Reproducible Results16
- Low Test Results15
- Incorrect, Inadequate or Imprecise Result or Readings4
- Output Problem4
- Unable to Obtain Readings3
- Signal Artifact/Noise2
- Incorrect Measurement1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions58
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Dimension Vista Total Bilirubin (TBIL) Flex Reagent Cartridge; Siemens Material Number (SMN): 10445146;Open, Classified
Siemens Healthcare Diagnostics, Inc.
Z-3065-2024 · Started Jul 30, 2024 · Posted by FDA Sep 6, 2024
Reason given: During manufacturing, the last three tests from the 160 test flex of lot 23206BA (wells 8 or 10) were processed on the Dimension Vista platform. There was an issue with the filling line which led to some wells to underfill in lot 23206BA. Calibrator, quality control (QC) and patient results could have been impacted.
Cause as FDA categorized it: Software Manufacturing/Software Deployment
- VITROS XT Chemistry Products TBIL-ALKP SlidesOpen, Classified
Ortho-Clinical Diagnostics, INc.
Z-2623-2023 · Started Aug 5, 2023 · Posted by FDA Sep 21, 2023
Reason given: Samples containing high levels of ALKP (or an interfering substance) could deplete the available substrate in the reagent layer of a VITROS ALKP Slide and not post the substrate deleption (DP) code, which may result in the System reporting an incorrect value (lower than the actual value), which may result in missed or...
Cause as FDA categorized it: Under Investigation by firm
Z-2874-2020 · Started Jul 13, 2020
Reason given: Etrombopag Interference for VITROS Chemistry Products: TBIL Slides, VITROS BuBc Slides and VITROS XT TBIL-ALKP Slides
Cause as FDA categorized it: Other
Z-2875-2020 · Started Jul 13, 2020
Reason given: Etrombopag Interference for VITROS Chemistry Products: TBIL Slides, VITROS BuBc Slides and VITROS XT TBIL-ALKP Slides
Cause as FDA categorized it: Other
Siemens Healthcare Diagnostics, Inc.
Z-1540-2020 · Started Feb 13, 2020
Reason given: Bilirubin assays may exhibit a positive bias with patients on eltrombopag therapy
Cause as FDA categorized it: Under Investigation by firm
Siemens Healthcare Diagnostics, Inc.
Z-1541-2020 · Started Feb 13, 2020
Reason given: Bilirubin assays may exhibit a positive bias with patients on eltrombopag therapy
Cause as FDA categorized it: Under Investigation by firm
Roche Diagnostics Operations, Inc.
Z-0153-2020 · Started Sep 11, 2019 · Posted by FDA Oct 16, 2019
Reason given: Due to low Quality Control recovery and invalid Calibration.
Cause as FDA categorized it: Under Investigation by firm
Z-1425-2020 · Started Aug 15, 2019
Reason given: It has been determined that N-acetyl p benzoquinone imine (NAPQI), a metabolite of acetaminophen (paracetamol), may cause negative interference for assays if present in high quantities in serum due to acetaminophen overdoese. This could result in a delay in diagnosis and treatment.
Cause as FDA categorized it: Device Design
Showing the 8 newest of 19 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.